CAU
LGND icon

Caxton Associates (UK)’s Ligand Pharmaceuticals LGND Stock Holding History

Caxton Associates (UK)’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.85M Sell
5,854
-12,797
-69% -$3.02M 0.03% 283
2026
Q1 		$3.72M Buy
18,651
+4,143
+29% +$820K 0.08% 94
2025
Q4 		$2.74M Hold
14,508
– – 0.05% 137
2025
Q3 		$2.57M Buy
+14,508
New +$2.16M 0.06% 149

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caxton Associates (UK)'s LGND Position: Q2 2026 in Review

Caxton Associates (UK) reduced its Ligand Pharmaceuticals (LGND) stake by 69% in Q2 2026, selling an estimated $3.02M and leaving 5,854 shares worth $1.85M. The position accounts for 0.03% of the portfolio, ranked #283.

Caxton Associates (UK) first reported a position in LGND in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.72M in Q1 2026. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Caxton Associates (UK) held 5,854 shares of Ligand Pharmaceuticals worth $1.85M as of Q2 2026.
  • Caxton Associates (UK) sold 12,797 Ligand Pharmaceuticals shares in Q2 2026, an estimated $3.02M.
  • Ligand Pharmaceuticals made up 0.03% of Caxton Associates (UK)'s portfolio in Q2 2026, its #283 holding.
  • Caxton Associates (UK) first reported a position in Ligand Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Caxton Associates (UK)'s Ligand Pharmaceuticals position peaked at $3.72M in Q1 2026.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.